Adjuvant systemic therapy for HER2-positive breast cancer - UpToDate
PDF) Dose Dense Doxorubicin and Cyclophosphamide Followed by Paclitaxel (Dose Dense AC Followed by T) Regimen for Breast Cancer
Sequential docetaxel as adjuvant chemotherapy for early breast cancer (TACT): an open-label, phase III, randomised controlled trial - The Lancet
Adjuvant systemic therapy for HER2-positive breast cancer - UpToDate
Anthracycline-free or short-term regimen as adjuvant chemotherapy for operable breast cancer: A phase III randomized non-inferiority trial - The Lancet Regional Health – Western Pacific
Chemotherapy protocol definition form | Download Scientific Diagram
SWOG S 0800 ( NCI CDR 0000636131 ) : addition of bevacizumab to neoadjuvant nab-paclitaxel with dose-dense doxorubicin and cyclophosphamide improves pathologic complete response ( pCR ) rates in inflammatory or locally
Pegylated liposomal doxorubicin plus cyclophosphamide followed by docetaxel as neoadjuvant chemotherapy in locally advanced breast cancer (registration number: ChiCTR1900023052) | Scientific Reports
The Red Devil Chemo: Tips for Managing Side Effects
Optimising dose-dense regimens for early breast cancer | Cancer World Archive
Standardizing Chemotherapy Regimen Nomenclature: A Proposal and Evaluation of the HemOnc and National Cancer Institute Thesaurus Regimen Content | JCO Clinical Cancer Informatics
HER2-Targeted Therapy for Early-Stage Breast Cancer: A Comprehensive Review
Update on systemic treatment for newly diagnosed inflammatory breast cancer - ScienceDirect
Chemotherapy for Uterus Cancer
Frontiers | Platinum and Taxane Based Adjuvant and Neoadjuvant Chemotherapy in Early Triple-Negative Breast Cancer: A Narrative Review
Dose-dense adjuvant chemotherapy in node-positive breast cancer: docetaxel followed by epirubicin/cyclophosphamide (T/EC), or the reverse sequence (EC/T), every 2 weeks, versus docetaxel, epirubicin and cyclophosphamide (TEC) every 3 weeks. AERO B03 ...
Neoadjuvant Chemotherapy Considerations in Triple-Negative Breast Cancer
Pregnancy-Associated Breast Cancer
Optimising dose-dense regimens for early breast cancer | Cancer World Archive
Treatment Switch in Poor Responders with Locally Advanced Gastric Cancer After Neoadjuvant Chemotherapy | SpringerLink
Dose-dense chemotherapy for breast cancer: what does the future hold? | Future Oncology
Current Oncology | Free Full-Text | Integrating Systematic Reviews into Supportive Care Trial Design: The Rethinking Clinical Trials (REaCT) Program
